Clinical trials: Influenza in Humans
Influenza
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to Havrix®, a licensed Hepatitis A virus vaccine.
- Trial name
- NCT01218308
- Testing
- FluLaval® Quadrivalent, Havrix™
- Where
- 12 sites in Bangladesh, Dominican Republic and 6 more
- Volunteers
- 5,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
To evaluate the safety of a single intramuscular (IM) injection of trivalent nonadjuvated influenza study vaccine, formulation 2012/2013, in adult and elderly subjects and the antibody response to each influenza vaccine antigen…
- Trial name
- NCT01636102
- Testing
- Trivalent influenza virus vaccine (TIV)
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza Type A, Influenza Type B
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc.
- Conditions
- Influenza Type A, Influenza Type B, Influenza
- Trial name
- NCT04471038
- Testing
- SAB-176, Normal Saline
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza, Respiratory Syncytial Viruses
The Respiratory Protection Effectiveness Clinical Trial
Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases.
- Conditions
- Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus
- Trial name
- ResPECT (NCT01249625)
- Testing
- N95 Respirator, Medical/surgical mask
- Where
- 7 sites in United States
- Volunteers
- 2,862 people
- Sponsor
- Johns Hopkins University
Respiratory Tract Infections, Influenza, Human
Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department
This is a randomized clinical trial to assess the effect of rapid, near point-of-care testing for multiple common respiratory viruses and bacteria on antibiotic and anti-influenza medication use in emergency department (ED)…
- Conditions
- Respiratory Tract Infections, Influenza, Human, Common Cold
- Trial name
- URIDxED (NCT02957136)
- Testing
- Rapid respiratory pathogen nucleic acid amplification test
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- University of California, Davis
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
- Trial name
- NCT00958126
- Testing
- CSL425
- Where
- 11 sites in United States
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Seqirus
Healthy
A Clinical Study to Assess the Safety of a New Influenza Vaccine
To assess the safety of a new influenza virus vaccine containing a new virus strain in healthy patients prior to the release of the vaccine.
- Trial name
- NCT01104493
- Testing
- Monovalent Frozen FluMist®
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Upper Respiratory Tract Infections
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu.
- Trial name
- NCT00895947
- Testing
- interferon-alpha
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Cytomegalovirus Infections, Influenza
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
In this study we are trying to understand whether previous infection with a particular virus, namely cytomegalovirus (CMV), influences the ability of the immune system to respond to new infections or vaccinations with age.
- Trial name
- SLVP025 (NCT02134184)
- Testing
- Fluzone® 2012-2013 Formula NDC No 498281-012-50
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
- Trial name
- NCT00735475
- Testing
- CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
- Where
- 13 sites in United States
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting…
- Trial name
- CAPSTONE 2 (NCT02949011)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 2,184 people
- Sponsor
- Shionogi
Influenza
Home Administration of FluMist by Parents/Caregivers
This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical…
- Trial name
- NCT01938170
- Testing
- FluMist
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
- Trial name
- NCT05566639
- Testing
- mRNA-1010, Fluarix Quadrivalent
- Where
- 233 sites in United States, Bulgaria and 9 more
- Volunteers
- 22,502 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Influenza
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older.
- Trial name
- NCT01430819
- Testing
- Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
- Where
- 6 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Adult Stem Cell Hematopoetic Transplant
Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not be significantly different from adult stem cell…
- Trial name
- NCT01215734
- Testing
- High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
- Trial name
- NCT01776554
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 12 sites in United States, Thailand
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
The aim of the study was to describe the safety and immunogenicity of a 0.5-mL dose (15 μg hemagglutinin [HA] per strain) of Fluzone Quadrivalent vaccine in children 6 to <36 months of age.
- Trial name
- NCT02915302
- Testing
- Fluzone Quadrivalent vaccine, No Preservative
- Where
- 36 sites in United States, United Kingdom
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company